Research programme: biodefence vaccines - CytoGenix/USAMRIID

Drug Profile

Research programme: biodefence vaccines - CytoGenix/USAMRIID

Alternative Names: Biodefense vaccines - CytoGenix/USAMRIID

Latest Information Update: 08 Jun 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CytoGenix; United States Army Medical Research Institute of Infectious Diseases
  • Class Vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Ebola virus infections; Encephalitis virus infections

Most Recent Events

  • 29 Mar 2007 CytoGenix establishes a CRADA with the USAMRIID for the development of synDNA™ vaccines for Ebola and encephalitis virus infections
  • 29 Mar 2007 Preclinical trials in Ebola virus infections in USA (unspecified route)
  • 29 Mar 2007 Preclinical trials in Encephalitis virus infections in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top